Changes in drug spending for different age groups during the 1990s? Evidence from Sweden

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 4, Issue 3, 2004, Pages 343-351

  Gerdtham, Ulf G ^a   Lundin, Douglas ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Age structure; Drug spending; Sweden

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; AGENTS ACTING ON THE GENITAL SYSTEM; ANTIASTHMATIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIINFECTIVE AGENT; ANTILIPEMIC AGENT; ANTIMIGRAINE AGENT; ANTITUSSIVE AGENT; ANTIULCER AGENT; ANTIVIRUS AGENT; BLOOD CLOTTING FACTOR; CALCIUM CHANNEL BLOCKING AGENT; CEPHALOSPORIN; CONTRACEPTIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTROGEN; FERTILITY PROMOTING AGENT; GESTAGEN; GROWTH HORMONE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INSULIN; INTERFERON; NEUROLEPTIC AGENT; OPIATE; SEDATIVE AGENT; TOPICAL AGENT; UNINDEXED DRUG;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANATOMY; CHILD; DRUG CLASSIFICATION; DRUG COST; DRUG DOSE REGIMEN; DRUG USE; FINANCIAL MANAGEMENT; GROUPS BY AGE; HUMAN; INFANT; POPULATION SIZE; PRESCRIPTION; REVIEW; STATISTICAL ANALYSIS; SWEDEN; TIME SERIES ANALYSIS; TREATMENT OUTCOME;

EID: 2942546076     PISSN: 14737167     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737167.4.3.343     Document Type: Review

References (12)

1. Gerdtham U-G, Johannesson M, Gunnarsson B, Marcusson M, Henriksson F. The effect on drug spending of changes in treatment patterns. PharmacoEconomics 13(1), 127-134 (1998).
2. Gerdtham U-G, Lundin D. Why did drug expenditure increase during the 90s? A decomposition of Swedish expenditure data. PharmacoEconomics 22(1), 29-42 (2004).
3. Merlis M. Explaining the growth in prescription drug spending: a review of recent studies. Report prepared for the US Department of Health and Human Services. 8 August 2000. US Department of Health and Human Services, Washington DC, USA (2000).
4. Morgan, SG. Quantifying components of drug expenditure inflation: the British Columbia seniors drug benefit plan. Health Serv. Res. 37(5), 1243-1266 (2002).
5. Mueller C, Chawla AJ, O'Connell J. Prescription drug spending: the impact of age and chronic disease status. Am. J. Pub. Health 87(10), 1626-4629 (1997).
6. Steinberg EP, Gutierrez B, Momani A, Boscarino JA, Neuman P, Deverka P. Beyond survey data: a claims-based analysis of drug use and spending by the elderly. Health Aff. 19(2), 198-211 (2000).
7. van Tielen R, Peys F, Genaert J. The demographic impact on ambulatory pharmaceutical expenditure in Belgium. Health Poli. 45(1), 1-14 (1998).
8. Crown W, Ling D, Berndt E. Measuring the costs and benefits of pharmaceutical expenditures. Expert Rev. Pharmacoeconomics Outcomes Res. 2, 89-97 (2002).
9. Dubois RW, Chawla AJ, Neslusan CA, Smith MW, Wade S. explaining drug spending trends: does perception match reality. Health Aff. 19(2), 231-239 (2000).
10. OECD Health Data. A software package for the international comparison of healthcare system, User's Manual. Version 1.01, Paris (2000).
11. Svensk Läkemedelsstatistik. Apoteket AB, Stockholm (2000).
12. Cutler D, Meara E. The medical costs of the young and old: a forty year perspective. NBER working paper 6114 (1997).